Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Rising Doses of BI 3032950 in Healthy Males
NCT05518708Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 3032950 in ulcerative colitis (UC) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of subjects with treatment-emergent adverse event up to 116 days. Started Sep 2022; status: completed.
02
Drugs
BI 3032950
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05518708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518708.